For the quarter ending 2025-12-31, PPCB had -$41,500 decrease in cash & cash equivalents over the period. -$1,001,407 in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | -3,091,394 | -4,837,738 | -58,923,300 |
| Issuance of common stock for services | 7,500 | 726,248 | 51,348,000 |
| Amortization of prepaid stock based expenses | 2,471,762 | 3,024,605 | 4,621,230 |
| Foreign currency transaction loss (gain) | -19,497 | -34,699 | -89,243 |
| Refundable advance deposit | - | - | 0 |
| Depreciation expense | 229 | 125 | 0 |
| Deferred offering costs | - | - | 0 |
| Amortization of debt discounts | 35,875 | 150,902 | 303,563 |
| Derivative expense | - | - | 333,596 |
| Amortization of right-of-use assets | 5,803 | 3,577 | 20,187 |
| Change in fair value of derivative liabilities | 87,728 | -19,706 | 212,450 |
| Change in fair value of warrant liability | -593,710 | - | - |
| Loss (gain) on extinguishment of debt, net | 14,317 | 195,861 | -871,032 |
| Allowance on refundable advance deposit | - | - | 0 |
| Non-cash interest expense | 937 | 4,906 | 5,519 |
| Accretion of put premium | 0 | -37,450 | 0 |
| Gst receivable | 8,572 | 3,043 | 2,405 |
| Prepaid expenses | -333,739 | 362,329 | -1,379 |
| Other current assets | - | 7,438 | - |
| Accounts payable | -123,564 | -186,804 | 187,732 |
| Employee benefit liability | 11,549 | 13,982 | 40,184 |
| Accrued expenses and other payables | 9,816 | -361,479 | 677,889 |
| Accrued interest | 22,151 | -3,298 | 255,155 |
| Operating lease liability | -6,151 | 2,723 | -21,722 |
| Net cash used in operating activities | -999,140 | -1,939,067 | -405,168 |
| Purchase of equipment | 2,267 | 2,491 | - |
| Proceeds from loans payable | - | - | 0 |
| Net cash used in investing activities | -2,267 | -2,491 | - |
| Proceeds from convertible promissory notes, net of original issue discounts and issue costs | 0 | 100,000 | 222,500 |
| Proceeds from issuance of convertible series c preferred stock, net of issuance cost | 950,099 | - | - |
| Repayment of convertible notes | 0 | 203,350 | 8,000 |
| Repayment of notes | 0 | 671,777 | 122,788 |
| Repayment of loans payable - related party | 0 | 150,808 | - |
| Proceeds from the sale of common stock, net of offering costs | 0 | 3,314,458 | 0 |
| Proceeds from note payable | 0 | 75,000 | 320,000 |
| Proceeds from loans payable - related parties | 0 | 78,249 | 343,700 |
| Deferred offering costs | - | 15,000 | 264,656 |
| Net cash provided by financing activities | 965,099 | 2,526,772 | 490,756 |
| Effect of exchange rate changes on cash | -5,192 | 5,435 | -94,585 |
| Net increase (decrease) in cash | -41,500 | 590,649 | -8,997 |
| Cash and cash equivalents at beginning of period | 602,737 | 12,088 | 21,085 |
| Cash and cash equivalents at end of period | 561,237 | 602,737 | 12,088 |
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc. (PPCB)